Back | Next |
home / stock / avir / avir message board
Subject | By | Source | When |
---|---|---|---|
wow went sub $11 and traded the whole | TheFinalCD | investorshub | 10/20/2021 2:05:48 AM |
Why $AVIR's AT-527 program is no-go: #msg-166425975. | DewDiligence | investorshub | 10/19/2021 11:52:46 PM |
David v Goliath | XWAVXALMIMAN | investorshub | 10/19/2021 7:57:45 PM |
What a drop | Chess Master | investorshub | 10/19/2021 2:59:46 PM |
Way over sold here. | ecommceo | investorshub | 10/19/2021 2:53:52 PM |
Out at $16, easy $$$ | Planopenny | investorshub | 10/19/2021 2:43:19 PM |
Let's go Brandon! FJB :) | Docstemcell2020 | investorshub | 10/19/2021 1:09:06 PM |
$AVIR CC slides (largely BS, IMO): | DewDiligence | investorshub | 10/19/2021 12:37:41 PM |
In at $10 | Planopenny | investorshub | 10/19/2021 12:23:25 PM |
Well the shit just hit the fan. | rosemountbomber | investorshub | 10/19/2021 11:47:34 AM |
Thanks DD | rosemountbomber | investorshub | 10/12/2021 12:47:40 PM |
The primary endpoint in $MRKs molnupiravir trial was | DewDiligence | investorshub | 10/12/2021 12:30:15 PM |
So I have to confess to my ignorance | rosemountbomber | investorshub | 10/12/2021 2:07:36 AM |
$AVIR presentation tomorrow Oct 5th | Whalatane | investorshub | 10/04/2021 6:54:23 PM |
You bet! > $AVIR up 45% @ 50.05 | crudeoil24 | investorshub | 10/01/2021 12:48:58 PM |
Thx for the updates Kiwi | Whalatane | investorshub | 10/01/2021 12:47:33 PM |
$AVIR up 45% @ 50.05 > premarket. | crudeoil24 | investorshub | 10/01/2021 12:40:29 PM |
$AVIR > 53M share trading float. | crudeoil24 | investorshub | 10/01/2021 11:48:39 AM |
Atea Pharmaceuticals to Present at Guggenheim 2nd Annual | crudeoil24 | investorshub | 10/01/2021 11:36:37 AM |
$AVIR up 30% @ 45.00 > As Barron's | crudeoil24 | investorshub | 10/01/2021 11:31:16 AM |
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...